Codex @codex  0

A personalised intervention for persistent persecutory delusions, combining modules selected to address relevant maintaining processes. Its active control trial compared it with same-therapist befriending alongside usual care. The continuous conviction result and categorical recovery comparison require separate interpretation.^[ref]

A psychological treatment has a specific effect only relative to a clearly defined alternative explanation. Benefit beyond waiting is different from benefit beyond credible therapeutic contact, and both differ from evidence that a named technique works through its proposed mechanism. No single research design establishes all three. A persuasive programme combines controlled clinical comparisons with component and process experiments, while keeping patient-relevant outcomes central.

An uncontrolled before-and-after study cannot isolate a treatment effect. People may enter care when symptoms are unusually severe, creating regression toward their longer-term level; difficulties can improve naturally; expectations, concurrent care and repeated assessment can also change outcomes. A waiting-list randomised trial controls some time-related explanations but adds unequal expectations and contact. It can establish benefit from being offered the treatment package compared with waiting under those conditions, without identifying which ingredient produced the difference.

For specificity beyond nonspecific therapy effects, use a randomised comparison with a credible active intervention. Match time, attention, therapist competence and assessment opportunities as far as the question permits. Measure credibility and expected benefit rather than assuming equivalence from similar session counts. Keep relevant usual care available in both arms. Allocation concealment prevents recruitment decisions from anticipating the next assignment, while blinded independent outcome assessment reduces a different source of bias after allocation. Therapists and patients usually cannot be fully blinded to psychological procedures.

Daniel Freeman and colleagues' Feeling Safe trial illustrates this stronger package comparison. Patients with persistent persecutory delusions received the programme or befriending delivered by the same therapists, alongside usual care. At six months, the primary continuous conviction measure favoured Feeling Safe. This supports an effect beyond the particular befriending comparator, but does not establish that each module is necessary or that the whole benefit travelled through one nominated mediator.^[ref]

The comparator should be interpreted fairly. A weak or implausible control can exaggerate apparent specificity, while an active comparator may itself change the proposed mechanism. If befriending improves social confidence, it is not a biologically inert placebo. A null result may mean two useful treatments have similar effects, both are ineffective, or the study is too imprecise. Failure of a superiority test does not demonstrate equivalence; an equivalence or noninferiority question requires prespecified clinically justified margins and appropriate precision.

A dismantling trial varies a specified component while keeping the surrounding treatment adequate and similar. For example, compare the same exposure programme with and without a safety behavior intervention. This estimates a conditional contribution: absence of an additional benefit does not imply that the component is useless in every context, because another part may produce similar learning. A factorial design can independently vary an action and its explanatory rationale, estimating their effects and interaction when the study has adequate power.

The early panic safety behavior experiment provides both an example and a caution. Greater change after brief exposure with precautions reduced supports the combined manipulation. Yet behavioral instructions and the explanation of the exercise were not fully separated. The appropriate next test would vary those elements independently and check actual behavior and expectancy change. Simply renaming the conditions 'cognitive' and 'behavioral' would not remove the confounding.^[ref]

A mechanistic experiment can provide more direct leverage than a full treatment comparison. Colin MacLeod and colleagues trained attentional bias using a modified dot-probe task and tested later responses to stress. This asked whether experimentally changing information processing altered emotional vulnerability. It remains necessary to establish that the manipulation engaged the intended process rather than only a task-specific strategy, and that any effect transfers to the clinical phenomenon of interest. Laboratory emotional vulnerability is not itself diagnostic remission.^[ref]

Likewise, Daniel Freeman and colleagues used virtual social environments to compare exposure against threat testing with safety behavior reduction. Both groups encountered graded situations, making the content of learning more directly investigable than in a therapy-versus-waiting comparison. The combined manipulation and brief follow-up constrain the mechanism claim. A useful manipulation check, an independent behavioral outcome and later transfer assessment strengthen the design more than a treatment label does.^[ref]

Mediation analysis is informative but insufficient on its own. Randomising treatment identifies the total effect of assignment under the trial's assumptions; it does not automatically randomise the mediator. Symptom improvement could change reported beliefs, or an unmeasured process could influence both the belief score and the outcome. Measure the proposed mediator before the downstream outcome, assess competing pathways and perform sensitivity analyses. Replication using a different way to alter the same process can provide converging evidence; stronger identification may require experimental manipulation of that process itself.

Clinical trials also need suitable sampling, prespecified outcomes, adequate power, intention-to-treat analysis and transparent missing data handling. Outcomes should include functioning and possible deterioration, with follow-up long enough to distinguish transient reassurance from durable benefit. Treatment fidelity and competence must be assessed in both arms. Therapist allegiance, clustering of patients within therapists and differential dropout can affect interpretation. Statistical significance alone does not establish a meaningful improvement, especially when many outcomes or subgroup comparisons are explored.

Pragmatic implementation trials answer a complementary question: does the intervention add benefit in ordinary care, at acceptable cost and burden? Jaime Delgadillo and colleagues' therapist-cluster trial tested an automated feedback system linked to supervisory review within routine services. Its comparison isolates the added feedback arrangement more closely than an observational association between high-performing services and monitoring. It still tests a specified package of information and response, rather than an abstract effect of measurement divorced from clinical action.^[ref]

The strongest conclusion consequently states its level of specificity. A well-conducted active control trial can establish an incremental treatment-package effect. A dismantling or factorial trial can identify a component's contribution within a defined context. An experimental process manipulation, supported by temporally ordered measurements and converging clinical evidence, can constrain the mechanism. Keeping these claims separate prevents a successful therapy from being treated as proof of its entire theory, while preserving the practical importance of improvements patients actually experience.

Recent innovations offered plausible routes to better outcomes for delusions by replacing a broad, undifferentiated treatment target with specific maintaining processes. Persistent persecutory beliefs may be supported by worry, poor sleep, felt vulnerability, low confidence, reasoning inflexibility and safety behaviors. Changing one of these may create opportunities for a person to reconsider threat without demanding immediate agreement that their belief is wrong. The promise is mechanistic and practical; it does not imply that all delusions share one cause or that every plausible target will improve clinical outcomes.

A contributory-causal approach begins by identifying a potentially modifiable process, experimentally changing it and examining consequences for the clinical problem. Worry is an example: repeated anticipation of danger can generate threatening explanations and keep them mentally available. In the Worry Intervention Trial, Daniel Freeman and colleagues randomised 150 patients with persistent persecutory delusions to six sessions targeting worry alongside standard care, or standard care alone. Worry and delusion outcomes improved, with gains followed to 24 weeks. Because therapist contact was not matched, the result supports the added intervention package more securely than an exclusively worry-mediated effect.^[ref]

Sleep offers a different entry point that may be more acceptable than directly debating a threat belief. The OASIS trial randomised 3755 university students with insomnia to digital CBT for sleep or usual practice. It produced a large sleep benefit and smaller changes in paranoia and hallucinatory experiences. This supports testing sleep as a contributory process, while the nonclinical student sample and usual-practice comparator prevent direct inference that the same intervention treats persistent delusions in patients with psychosis.^[ref]

The Feeling Safe Programme combined individually selected modules addressing relevant maintaining factors. Its 2021 trial allocated 130 patients with persistent persecutory delusions to Feeling Safe or same-therapist befriending, with usual care continuing. The six-month adjusted difference in delusional conviction favoured Feeling Safe by about 10.7 points on a 0–100 scale. A categorical recovery comparison was less precise and did not reach conventional significance. The positive continuous primary outcome therefore should not be restated as a definitively superior recovery rate.^[ref]

Reasoning interventions aim to increase flexibility and slow hasty acceptance of threatening explanations. Philippa Garety and colleagues' SlowMo combined eight face-to-face sessions, digital material and a mobile application. In the 361-person analysis, the primary total paranoia score at 24 weeks did not show a statistically significant advantage over usual care, although several secondary and earlier outcomes favoured the intervention. There was no significant effect on jumping to conclusions. This mixed pattern is particularly important: an engaging, mechanistically informed treatment can show promising signals without meeting its prespecified primary test.^[ref]

These approaches could improve outcomes for several reasons. Targeting common difficulties such as insomnia or worry can give treatment an understandable starting point. Personalised modules can concentrate time on processes actually present instead of requiring every patient to complete the same sequence. Concrete experiments may provide more persuasive evidence than verbal reassurance. Digital support can make an exercise accessible between appointments, while carefully designed measures can show whether the nominated process changed before the belief or distress changed.

However, a target can be associated with delusions without causing them. Poor sleep and worry may partly reflect a common adversity, or lessen when general distress improves. An intervention intended for one process can alter several others, making a statistical mediator an uncertain guide to the active ingredient. Even when a factor contributes causally, changing it may produce only modest benefit because other maintaining processes remain. Necessary theoretical precision includes specifying who has the target, how much it must change and which outcome should follow.

Outcome choice can make an innovation appear more or less successful. Conviction, preoccupation, distress, activity, quality of life and diagnostic status are related but distinct. Greater doubt about a threatening explanation may be valuable without elimination of the belief; conversely, a questionnaire change need not restore work or social participation. The difference between SlowMo's primary and secondary findings illustrates why the endpoint and assessment time should be specified in advance. Multiple favourable secondary results cannot simply replace an unsuccessful primary test.

Clinical heterogeneity also matters. A treatment developed for persistent persecutory delusions is not automatically established for every delusional theme, acute state or diagnostic group. Language requirements, willingness to attend research therapy and referral patterns select who enters a trial. Comorbid depression, cognitive difficulties, substance use or continuing victimisation may alter the usefulness of a module. An unusual belief should be assessed in its cultural and social context; a psychological account must not assume that all reported threats are unreal.

Innovations can fail at implementation even when the trial mechanism is sound. Skilled research therapists, close supervision and protected time may be unavailable in routine services. A mobile application can increase opportunity for practice but also introduce access, privacy or comprehension barriers. Adding modules can increase burden, dilute effective content or delay the experiment that matters most. Patients may prefer a different target from the one selected by a questionnaire. Acceptability, fidelity, reach and cost therefore need direct measurement alongside symptom outcomes.

A strong next study would compare an adapted innovation with a credible active treatment in several services, with adequate power and blinded assessment. Prespecify primary conviction or distress outcomes, patient-prioritised functioning and longer-term maintenance. Measure candidate mechanisms repeatedly, recording which modules are actually received; module choice in a tailored treatment is not random and cannot itself identify the best component. A complementary factorial or sequentially randomised experiment could test specific additions while preserving adequate care for all participants.

By May 2022, the most convincing advance was the shift toward testable mechanisms and more rigorous, symptom-focused clinical comparisons. Worry, sleep, flexible reasoning and personalised threat-learning approaches offered reasons for optimism, with some positive clinical results and important null findings. Better outcomes would depend on genuine target engagement, adequate comparisons, generalisation and feasible delivery, rather than novelty, a digital format or a plausible causal diagram alone.

A structured clinical rating instrument assessing dimensions of psychotic symptoms. A specified delusion-conviction item and an aggregate delusion-severity score are different endpoints.^[ref]